High-Purity, Low-Endotoxin Carbohydrates, Parenteral Grade Excipients and Highly Potent APIs
Vice-president of research and development (R&D) Dr. Trevor Calkins discusses Pfanstiehl’s active pharmaceutical ingredients (API) contract development and manufacturing organisation (CDMO) philosophy and capabilities at the CPhI/InformEx exhibition in Philadelphia.
Pfanstiehl offers a wide array of API development services at its campus just north of Chicago. The company has one of the first Safebridge-certified facilities in the world and is passionate about solving complex chemistry challenges. The company is focused on being in lockstep with clients from early preclinical through commercialisation.